1Thun MJ,Henley SJ,Patrono C.Nonsteroidal antiinflammatory drugs as anticancer agents:mechanistic,pharmacologic,and clinical issues.J Natl Cancer Inst,2002,94:252-266.
2Soumaoro LT,Uetake H,Higuchi T,et al.Cyclooxygenase-2 expression:a significant prognostic indicator for patients with colorectal cancer.Clin Cancer Res,2004,10:8465-8471.
3Shibata M,Kodani I,Osaki M,et al.Cyclo-oxygenase-1 and -2 expression in human oral mucosa,dysplasias and squamous cell carcinomas and their pathological significance.OralOncol,2005,41:304-312.
4Kim N,Kim CH,Ahn DW,et al.Anti-gastric cancer effects of celecoxib,a selective COX-2 inhibitor,through inhibition of Akt signaling.J Gastroenterol Hepatol,2009,24:480-487.
5Kinugasa Y,Hatori M,Ito H,et al.Inhibition of cyclooxygenase-2 suppresses invasiveness of oral squamous cell carcinoma cell lines via down-regulation of matrix metalloproteinase-2 and CD44.Clin Exp Metastasis,2004,21:737-745.
6Valsecchi ME,Pomerantz SC,Jaslow R,et al.Reduced risk of bone metastasis for patients with breast cancer who use COX-2 inhibitors.Clin Breast Cancer,2009,9:225-230.
7Shin YK,Park JS,Kim HS,et al.Radiosensitivity enhancement by celecoxib,a cyclooxygenase (COX)-2 selective inhibitor,via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels.Cancer Res,2005,65:9501-9509.
8Ferrari V,Valcamonico F,Amoroso V,et al.Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer:a phase Ⅱ trial.Cancer Chemother Pharmacol,2006,57:185-190.
9Elder DJ,Halton DE,Hague A,et al.Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal antiinflammatory drug:independence from COX-2 protein expression.Clin Cancer Res,1997,3:1679-1683.
10Piazza GA,Rahm Ak,Finn TS,et al.Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition,cell cycle arrest,and p53 induction.Cancer Res,1997,57:2452-2459.
